Free Trial
NASDAQ:TNYA

Tenaya Therapeutics Q1 2023 Earnings Report

Tenaya Therapeutics logo
$0.44 -0.01 (-2.07%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$0.44 0.00 (-0.14%)
As of 05/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

Tenaya Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenaya Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Wednesday, May 10, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Tenaya Therapeutics' Q2 2025 earnings is scheduled for Tuesday, May 13, 2025

Tenaya Therapeutics Earnings Headlines

Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Tenaya announces interim data from ongoing RIDGE study
See More Tenaya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email.

About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ:TNYA), a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Tenaya Therapeutics Profile

More Earnings Resources from MarketBeat